AK112
AK112 is a pharmaceutical drug with 38 clinical trials. Currently 24 active trials ongoing. Historical success rate of 87.5%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
17
Early Stage
16
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
87.5%
7 of 8 finished
12.5%
1 ended early
24
trials recruiting
38
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
AMT-116 in Combination With Ivosidan in Patients With Lung Cancer
OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Clinical Trials (38)
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
AMT-116 in Combination With Ivosidan in Patients With Lung Cancer
OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
AK112 in Advanced Non-Small Cell Lung Cancer
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
A Study of AK112 in Advanced Malignant Tumors
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 38